Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Healthcare Sector Analysis

UpdatedAug 10, 2026
DataAggregated Company Financials
Companies34
  • 7D2.7%
  • 3M12.0%
  • 1Y30.6%
  • YTD12.3%

The Healthcare industry is up 2.7% in the last week, with Roche Holding up 3.2%. This takes the industry's 12 month performance to a gain of 31%. Earnings are forecast to grow by 13% annually.

Sector Valuation and Performance

Has the Swiss Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 10 Aug 2026CHF 741.7bCHF 157.5bCHF 27.2b33.3x27.3x4.7x
Wed, 08 Jul 2026CHF 706.4bCHF 156.4bCHF 28.3b33.8x25x4.5x
Fri, 05 Jun 2026CHF 658.4bCHF 154.8bCHF 28.0b33.3x23.5x4.3x
Sun, 03 May 2026CHF 661.3bCHF 154.3bCHF 28.0b32.2x23.6x4.3x
Tue, 31 Mar 2026CHF 662.6bCHF 155.8bCHF 28.7b32.9x23.1x4.3x
Thu, 26 Feb 2026CHF 740.5bCHF 152.5bCHF 27.7b32.4x26.8x4.9x
Sat, 24 Jan 2026CHF 720.3bCHF 154.0bCHF 24.7b32.7x29.1x4.7x
Mon, 22 Dec 2025CHF 681.8bCHF 154.6bCHF 24.9b29.4x27.4x4.4x
Wed, 19 Nov 2025CHF 642.3bCHF 154.9bCHF 24.9b27.2x25.8x4.1x
Fri, 17 Oct 2025CHF 630.4bCHF 153.3bCHF 24.1b31.3x26.1x4.1x
Sun, 14 Sep 2025CHF 609.0bCHF 153.5bCHF 24.1b32.6x25.2x4x
Tue, 12 Aug 2025CHF 587.6bCHF 154.5bCHF 24.4b29.1x24.1x3.8x
Thu, 10 Jul 2025CHF 590.0bCHF 149.6bCHF 22.2b30x26.6x3.9x
Sat, 07 Jun 2025CHF 596.8bCHF 151.8bCHF 22.6b30.8x26.4x3.9x
Mon, 05 May 2025CHF 591.4bCHF 151.8bCHF 22.5b31x26.2x3.9x
Wed, 02 Apr 2025CHF 603.8bCHF 155.0bCHF 22.5b29.5x26.8x3.9x
Fri, 28 Feb 2025CHF 629.1bCHF 155.6bCHF 22.4b26.4x28.1x4x
Sun, 26 Jan 2025CHF 604.1bCHF 152.7bCHF 24.5b31.1x24.6x4x
Tue, 24 Dec 2024CHF 562.0bCHF 152.2bCHF 24.4b28.4x23x3.7x
Thu, 21 Nov 2024CHF 565.7bCHF 151.1bCHF 24.3b29.2x23.3x3.7x
Sat, 19 Oct 2024CHF 618.7bCHF 148.5bCHF 22.6b31.2x27.4x4.2x
Mon, 16 Sep 2024CHF 604.8bCHF 147.2bCHF 22.3b32.8x27.1x4.1x
Wed, 14 Aug 2024CHF 607.3bCHF 148.1bCHF 22.3b27.1x27.2x4.1x
Fri, 12 Jul 2024CHF 592.0bCHF 148.9bCHF 22.7b38.1x26.1x4x
Sun, 09 Jun 2024CHF 572.5bCHF 148.9bCHF 22.7b35.4x25.2x3.8x
Tue, 07 May 2024CHF 530.3bCHF 145.8bCHF 22.8b32.8x23.2x3.6x
Thu, 04 Apr 2024CHF 549.8bCHF 144.5bCHF 22.3b35.9x24.7x3.8x
Sat, 02 Mar 2024CHF 531.8bCHF 143.2bCHF 22.7b36.4x23.5x3.7x
Mon, 29 Jan 2024CHF 546.3bCHF 152.6bCHF 21.4b34x25.5x3.6x
Wed, 27 Dec 2023CHF 522.8bCHF 151.7bCHF 21.8b26.3x23.9x3.4x
Fri, 24 Nov 2023CHF 514.4bCHF 153.8bCHF 22.1b24.6x23.3x3.3x
Sun, 22 Oct 2023CHF 505.6bCHF 153.2bCHF 21.6b25.7x23.4x3.3x
Tue, 19 Sep 2023CHF 541.4bCHF 145.0bCHF 21.1b32.7x25.6x3.7x
Thu, 17 Aug 2023CHF 546.2bCHF 143.8bCHF 21.1b31.6x25.9x3.8x
Price to Earnings Ratio

25.9x


Total Market Cap: CHF 546.2bTotal Earnings: CHF 21.1bTotal Revenue: CHF 143.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Healthcare Sector Price to Earnings3Y Average 25.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 25.3x.
  • The 3-year average PS ratio of 4.0x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 8.8% per year over the last three years.
  • Revenues for these companies have grown 3.1% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare sector?

CH Market1.49%
Healthcare2.65%
Healthtech9.98%
Pharma2.94%
Life Sciences1.62%
Medical Equipment1.29%
Biotech1.09%
Healthcare Services-2.02%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 47.0x.
    • Analysts are expecting annual earnings growth of 19.3%, which is higher than its past year's earnings growth of 8.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 39% over the next 5 years.
  • This is better than its past earnings decline of 48% per year.
  • In contrast, the Healthtech industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 373.104.8%
+CHF 13.6b		51.5%PE24.1x
NOVN NovartisCHF 126.801.8%
+CHF 4.4b		32.1%PE23.4x
SDZ Sandoz GroupCHF 72.2612.9%
+CHF 3.6b		53.6%PE59.9x
LONN Lonza GroupCHF 579.603.5%
+CHF 1.4b		7.1%PE37.4x
ALC AlconCHF 58.323.0%
+CHF 829.1m		-15.6%PE42.9x

Latest News

GALE
CHF 82.20
Galenica
7D
-2.8%
1Y
-4.0%
SDZ
CHF 72.26
Sandoz Group
7D
12.9%
1Y
53.6%
BANB
CHF 74.50
Bachem Holding
7D
-0.5%
1Y
11.2%
MOVE
CHF 131.40
Medacta Group
7D
-0.6%
1Y
-11.5%
Analysis Article • Aug 05

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
ROP
CHF 373.10
Roche Holding
7D
4.8%
1Y
51.5%
NOVN
CHF 126.80
Novartis
7D
1.8%
1Y
32.1%
YPSN
CHF 400.00
Ypsomed Holding
7D
4.0%
1Y
2.2%
Narrative Update • Jul 30

YPSN: Long Term Delivery Demand And Dividend Payout Will Support Upside

The analyst price target for Ypsomed Holding has been revised from CHF 440 to CHF 455 as analysts factor in mixed recent research, including concern about Cagrisema related sales pressure, along with more constructive views from other firms. Analyst Commentary Recent research on Ypsomed Holding highlights a split view.
GALD
CHF 175.95
Galderma Group
7D
1.1%
1Y
32.5%
Narrative Update • Jul 30

GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction

Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.
LONN
CHF 579.60
Lonza Group
7D
3.5%
1Y
7.1%
Narrative Update • Jul 24

LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside

Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.
SOON
CHF 237.40
Sonova Holding
7D
3.8%
1Y
6.0%
Narrative Update • Jul 22

SOON: Mixed Rating Shifts And Dividend Outlook May Steady P E Over Time

The analyst price target for Sonova Holding has been raised from CHF 216.51 to CHF 221.83, as analysts cite relative valuation versus peers and indications of a possible growth inflection in recent sector research. Analyst Commentary Recent research on Sonova Holding shows a mix of optimism about potential growth and ongoing caution around valuation and execution, giving you a more balanced view of how the stock is being framed by the market.
ALC
CHF 58.32
Alcon
7D
3.0%
1Y
-15.6%
Narrative Update • Jul 21

ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook

Analysts have trimmed their Alcon price target to CHF56.59 from CHF57.82, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E levels. What's in the News for Alcon Alcon and RxSight entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight’s postoperative light-adjustable technology with Alcon’s PCIOL optical designs to allow surgeons to fine-tune vision for cataract patients after surgery.
MOLN
CHF 3.27
Molecular Partners
7D
-2.7%
1Y
14.1%
VBSN
CHF 125.00
IVF Hartmann Holding
7D
-1.2%
1Y
-10.4%
METN
CHF 785.00
Metall Zug
7D
-1.3%
1Y
-21.5%
MED
CHF 84.50
Medartis Holding
7D
-5.2%
1Y
5.9%
Narrative Update • Jun 23

MED: Award Recognition And Steady Assumptions Will Support Future Upside

The analyst price target for Medartis Holding has been trimmed slightly from CHF 95.97 to CHF 95.00, reflecting small updates to fair value inputs, discount rate, revenue growth, profit margin and future P/E assumptions cited by analysts. What's in the News Medartis Holding received the 2026 Swiss Medtech Award for its titanium implant systems, a recognition of its work in clinically focused product development and collaboration with surgeons.
CURN
CHF 20.30
Curatis Holding
7D
-3.3%
1Y
69.2%